Between Bangalore and Chennai in the Indian state of Andhra Pradesh, you’ll find the town of Tirupati. It’s home to seven peaks that host a Hindu temple complex devoted to a form of Vishnu, Venkateshvara. It is also the region from which Upendra Marathi originally hails. It’s where his father, and many other family members, attended medical school.
“My father’s first job was to take care of the pilgrims,” recalls Marathi.
It's only natural that his groundbreaking Houston company would be named 7 Hills Pharma.
“That sort of selflessness and giving back, I wanted to embody it in the name of the company,” Marathi says.
Now, 7 Hills Pharma is announcing that last month, it was awarded a $13.5 million grant from the Cancer Prevention and Research Institute of Texas (CPRIT). That’s on top of more than $13 million in NIH grants, making the company the second largest recipient of SBIR/STTR grants in Texas.
Launched in 2016, 7 Hills Pharma is working to develop drugs that can overcome the all-too-common problem of immunotherapy resistance. Thanks to the Nobel Prize-winning work of Jim Allison in the realm of immuno-oncology, the field was “very hot” at the time, says Marathi, particularly in Houston.
So what has 7 Hills developed? Oral small molecules that activate integrins — the receptors that allow cells to bind to one another — allowing for the cell-to-cell interactions that create a successful immune response to immune checkpoint inhibitors such as Yervoy. In other words, they have created capsules that increase the effectiveness of drugs that allow the body’s own immune response to fight cancers.
But that’s not all. Tests have shown that the same discovery, called alintegimod, can also augment the effectiveness of vaccines. The pill, which co-founder and co-inventor Peter Vanderslice calls “a beautiful way to amplify the vaccines,” can potentially be applied to anything from influenza to coronavirus.
Their greatest challenge, says Vanderslice, is the very fact that the technology is so novel.
“Most large pharmas are very risk averse,” he explains. “They only want to do ‘me-too’ kinds of drugs.”
7 Hills Pharma is the third company Marathi, both a PhD and an MBA, has helped to found based on technology he co-invented. Vanderslice is director of the molecular cardiology research laboratories at The Texas Heart Institute.
“It’s very much a homegrown company,” Marathi says.
And a small one, at least for now. Working out of JLabs@TMC, the full-time team is currently just Marathi and Siddhartha De, the senior director of development. Marathi convinced De to transplant himself and his family from India for the purpose of assisting 7 Hills with preparing its drugs for clinical readiness.
The CPRIT funds will allow 7 Hills Pharma to hire several long-time team members full-time and with benefits.
“The bringing of talent and bringing of technology to TMC and what was born at Texas Heart Institute is rather remarkable,” says Rob Bent, the company’s director of operations.
The next step for 7 Hills Pharma is a Phase Ib/IIa clinical trial in patients with treatment-resistant solid tumors. And the team just finalized the deck that will help raise another $10 million to $250 million in the company’s series A. And hopefully sooner rather than later, a new set of medical pilgrims will be thanking 7 Hill Pharma for its care.
- Here's what Houston cancer researchers secured fresh funding from Texas nonprofit ›
- Seattle biotech co. to move to Houston thanks to $13.3M grant from Texas organization ›
- Texas nonprofit cancer research funder doles out millions to health professionals moving to Houston ›
- Joseph Rogers of Texas Heart Institute on the Houston Innovators Podcast - InnovationMap ›
- CPRIT doles out $49M to Baylor College of Medicine, MD Anderson, and more - InnovationMap ›
- CPRIT funds Stingray Therapeutics, March Biosciences, Mongoose Bio, and FixNip - InnovationMap ›
- CPRIT grants $68.5M to Houston organizations - InnovationMap ›
